A step towards understanding the molecular nature of human heart failure: advances using the Sydney Heart Bank collection
The Sydney Heart Bank (SHB) primarily contains tissues from hearts that were either derived from patients undergoing an isotopic heart transplantation or were from non-failing donor hearts. The latter had no apparent disease but were not required or not suitable for transplantation. Several review articles have been written (dos Remedios et al. 2017, 2018; Lal et al. 2015; Li et al. 2013), but none has attempted to summarise all causes of the failing hearts in the SHB. This review gathers the relevant information about the heart tissue from 450 patients with cardiomyopathies and 120 healthy donor hearts.
Our aim is to give readers the ability to assess whether the SHB contains tissue that might be useful for proposed experiments, particularly where prospective users have preliminary data based on animal models of human heart failure. We are often contacted by researchers who have data from failing or diseased human heart tissue but have no access to healthy donors. Few realise that the...
Compliance with ethical standards
Conflict of interest
Amy Li declares that she has no conflict of interest. Sean Lal declares that he has no conflict of interest. Cristobal G. dos Remedios declares that he has no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- dos Remedios CG, Li A, Lal S (2018) Non-sarcomeric causes of Heart failure: a Sydney Heart Bank perspective. Biophys Rev 10(4):949–954. https://doi.org/10.1007/s12551-018-0441-4
- Huang Z-P, Ding Y, Chen J, Wu G, Kataoka M, Hu Y, Yang J-H, Liu J, Drakos SG, Selzman CH, Kyselovic J, Qu L-H, dos Remedios CG, Pu WT, Wang D-Z (2016) Long non-coding RNAs link extracellular matrix gene expression to ischemic cardiomyopathy. Cardiovasc Res 112:543–554. https://doi.org/10.1093/cvr/cvw201 CrossRefGoogle Scholar
- Klauke B, Gaertner-Rommel A, Schulz U, Kassner A, Zu Knyphausen E et al (2017) High proportion of genetic cases in patients with advanced cardiomyopathy including a novel homozygous Plakophilin 2-gene mutation. PLoS One 12:e0189489. https://doi.org/10.1371/journal.pone.0189489 CrossRefGoogle Scholar
- Lin Z, Guo H, Cao Y, Zohrabian S, Zhou P, Ma Q, VanDusen N, Guo Y, Zhang J, Stevens SM, Liang F, Quan Q, van Gorp PR, Li A, dos Remedios C, He A, Bezzerides VJ, Pu WT (2016) Acetylation of VGLL4 regulates hippo-YAP signaling and postnatal growth. Dev Cell 39:466–479. https://doi.org/10.1016/j.devcel.2016.09.005 CrossRefGoogle Scholar
- Messer AE, Bayliss CR, El-Mezgueldi M, Redwood CS, Ward DG et al (2016) Mutations in troponin T associated with hypertrophic cardiomyopathy increase Ca2+−sensitivity and suppress the modulation of Ca2+−sensitivity by troponin I phosphorylation. Arch Biochem Biophys 601:113–120. https://doi.org/10.1016/j.abb.2016.03.027 CrossRefGoogle Scholar
- Polizzotti BD, Ganapathy B, Walsh S, Choudhury S, Ammanamanchi N et al (2015) Stimulation of cardiomyocyte regeneration in neonatal mice and in human myocardium with neuregulin reveals a therapeutic window. Sci Translat Medic 7. https://doi.org/10.1126/scitranslmed.aaa5171
- Sequeira V, Wijnker PJM, Nijenkamp LAM, Najafi A, Rosalie Witjas-Paalberends (2013) Perturbed length-dependent activation in human hypertrophic cardiomyopathy with sarcomere mutations in myosin and thin filament proteins. Circ Res 112:1491–1505Google Scholar